Germany
Your success factors - Biotech Business in Germany
- Germany enjoys a leading position in a number of innovative technologies, is first rate in the chemical sector, and leading in the optical technologies, medical technology, nano-technology, and biotechnologies.
- Germany is world export champion in a number of branches. Its pharmaceutical industry is the world's largest exporter of medications and drugs.
- Germany is the most populous country in the EU and offers a high-level health system.
- Germany features a central location for access to a market of 27 EU countries and 490 million people with a share of about 25 % of the income of the world's population.
- Germany is already Europe's "Number One" as biotech production site products.
- Germany features internationally celebrated research institutions such as
- the Max-Planck-Gesellschaft,
- the Helmholtz-Gemeinschaft Deutscher Forschungszentren, and
- the Fraunhofer Gesellschaft, strong magnets for leading figures in international science.
- Germany has excellent universities and a famous vocational training system with top-rate experts in many areas.
- Result: 60 % of all European patent registrations come from Germany.
- Germany is providing some 15 billion Euros for promotion of cutting-edge technologies up to the year 2009. Our target: by 2010 increase to 3% of the share of GDP accounted for by research.
- Germany assists with this High-Tech Strategy above all cutting-edge technologies such as the modern biotechnologies.
- With the targeted promotion of clusters, the German government is specifically supporting the exchange process between science and business and among the various disciplines.
- In Germany, start-ups and the growth of high-tech companies are being successfully assisted through the High-Tech-Start-Up Fund, ERP Start-Up Fund, and the EIF/ERP-Umbrella Fund.
- Knowledge is being converted into marketable products in 30 bio regions.
- BIOTECHNICA, Europe's leading trade fair for the biotechnologies, is held in Germany (Hanover 09-11 October 2007).
Further Information/Contacts: